Locating in the heart of Middle East, right beside the biggest narcotic producer in the world, and with an increasing number of injecting drug users, viral hepatitis is considered as a serious risk factor in our country, Iran. The prevalence of HCV in general population In Iran is about 0.3% that is not very high, but it’s considerably different from its prevalence among high risk population with 32.1%; and the prevalence among drug injecting users subpopulation is 52.2%, horrifying. As a full member of IPPF, and with special consultative status in the UN-ECOSOC, we decided to put hepatitis in our domain of concerns since last year and we’ve started our mission with HCV. We are screening our clients that are mostly high risk women in the poorest neighborhood of Tehran for HCV and with the help of donors and medical facilities, putting them under treatment. Beside the direct services we are providing in our DICs in, we’ve started our advocacy programs to educate the society about this ticking bomb and engaging authorities and the other NGOs to tackle this problem. It’s our first step of many we’re going to take.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close
